Duolingo Inc vs Nuwellis Inc — how do they compare? Duolingo Inc trades at $128.96 (market cap $5.98B), while Nuwellis Inc trades at $3.16 (market cap $1.17M). The key difference: Duolingo Inc is far larger — about 5111.1× Nuwellis Inc's market cap, and Duolingo Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| DUOL | NUWE | |
|---|---|---|
Market Cap | $5.98B | $1.17M |
Sector | Technology | Technology |
52-Week High | $390.84 | $558.26 |
52-Week Low | $90.03 | $2.80 |
Enterprise Value | $4.82B | -$636.97K |
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $132.34, up 6.08% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $127 and resistance at $135. Fundamentally, revenue grew to $1.04 billion in 2025, with net income surging to $414 million, driven by robust user engagement and AI feature expansion. Recent earnings beats and a positive analyst consensus highlight investor confidence in the company's growth trajectory.
Outlook remains positive with AI-driven user growth and profitability, but risks include rising inference costs and competitive pressures. The stock offers growth potential, yet investors should monitor margin trends and market volatility. Analyst price targets suggest moderate upside from current levels, with a consensus of $108.29.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Trailing returns across standard periods
Latest headlines on both assets
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →